VU0359595

Confirm delete?

VU0359595

Zoom

Cat No: 10955

Biochemicals - Small Molecule Inhibitors

Phospholipase D (PLD) is an enzyme that cleaves the head group from phospholipids, producing the second messenger phosphatidic acid. Two mammalian isoforms of PLD, PLD1, and PLD2, have been identified, with multiple splice variants of each. Although th...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

(1R,2R)-N-[(1S)-2-[4-(5-bromo-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-1-methylethyl]-2-phenyl-cyclopropanecarboxamide; (1S,2S)-N-[(1S)-2-[4-(5-bromo-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-1-methylethyl]-2-phenyl-cyclopropanecarboxamide

Correlated keywords:

1246303-14-9 1257404-85-5 molecular library initiative agonists CID-53361951 CID53361951 CIDs 53361951 ML270 MLs 270 ML-270 PLD1 phophoslipases D inhibitors PLDs PLD-1 VUs 0359595 VU-0359595 inhibits inhibitions PLs phosphatidic acids isoforms binds binding binders allosteric sitesselective cell biology intracellular signaling transductions

Product Overview:
Phospholipase D (PLD) is an enzyme that cleaves the head group from phospholipids, producing the second messenger phosphatidic acid. Two mammalian isoforms of PLD, PLD1, and PLD2, have been identified, with multiple splice variants of each. Although the two isoforms share structural and functional features, they are regulated differently and apparently subserve distinct roles. VU0359595 is an inhibitor of PLD1 (IC50 = 3.7 nM) that is >1,700-fold selective over PLD2 (IC50 = 6.4 μM).{24567} Preliminary evidence suggests that VU0359595 does not interact with the catalytic site of PLD, but instead may bind and inhibit PLD through an allosteric site.{24567}

Size	1 mg
Shipping	dry ice
Molecular Formula	C₂₅H₂₉BrN₄O₂
SMILES	C[C@@H](CN1CCC(CC1)N2C(NC3=C2C=CC(Br)=C3)=O)NC([C@@H]4C[C@H]4C5=CC=CC=C5)=O.C[C@@H](CN6CCC(CC6)N7C(NC8=C7C=CC(Br)=C8)=O)NC([C@H]9C[C@@H]9C%10=CC=CC=C%10)=O
Molecular Weight	497,4
Formulation	A crystalline solid
Purity	≥95% (mixture of diastereomers)
Custom Code	2933.39
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.